Massimo Cristofanilli, MD, FACP
Clinician + Researcher
Title(s)
- President, Inflammatory Breast Cancer International Consortium
- Professor of Medicine (Hematology and Oncology), Northwestern Medicine Feinberg School of Medicine
Location(s)
- Maggie Daley Center for Women’s Cancer Care
- 250 E. Superior Street, Suite 4-420
- Prentice Women’s Hospital
- Chicago, IL, 60611
- United States of America
- Phone: 866.587.4322
- Fax: 312.472.4784
Research and Clinical Interests
IBC-Focused Research
I am a physician-scientist known for contributions in several areas of clinical and translational research—one of which is the research and treatment of inflammatory breast cancer (IBC), the most aggressive and deadly form of breast cancer.
I have worked for many years in defining the unique biological and clinical aspects of IBC. I started the Morgan Welch IBC Research Program and Clinic, the first of its kind solely dedicated to this disease. The International Collaboration in IBC research has increased with the creation of the IBC International Consortium (IBC-IC) with IBC International Conferences held every two years. These events contribute to increased awareness and understanding of the disease and the development of dedicated clinical trials to improve the outcome for these patients.
Clinical interests
- Advanced Molecular Diagnostics
- Breast Cancer
- Endocrine Resistance
- Inflammatory Breast Cancer
- Metastatic Breast Cancer
Education and Board Certifications
MD
University La Sapienza, Rome, Italy (1986)
Internship
Cabrini Medical Center, New York, NY, Internal Medicine (1994)
Residency
Cabrini Medical Center, New York, NY, Chief Medical Resident (1996)
Fellowship
University of Texas/MD Anderson Cancer Center, Medical Oncology (1998)
Board Certification(s)
American Board of Internal Medicine - Medical Oncology
Years in Practice
31
Affiliations and Memberships
Recent Publications
Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer
Breast Cancer Research and Treatment; July 7, 2017
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients
Breast Cancer Research and Treatment; March 7, 2017
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer:
New discoveries and practical insights for drug development
Cancer Treatment Reviews; February 2017
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in
patients with inflammatory breast cancer
Oncotarget; January 2017
Clinical Trials
NU UW16B13: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
NU 17B02: Phase II single arm of BYL719/Alpelisib combined with chemotherapy for neoadjuvant treatment of patients with HER2-negative stage III inflammatory breast cancer (IBC) — I-TARGET-IBC Trial
Affiliated IBC-IC Center(s)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Chicago, IL, 60611
- Research + Treatment Center
Join IBC-IC
Become part of our international consortium of researchers, clinicians, advocates and centers worldwide dedicated to ending IBC.
Join >IBCIC.org makes every effort to keep researcher information as up-to-date as possible.
Contact this researcher to confirm any information regarding his or her profile.